Investing in South Africa
Indian pharma opens new plant in SA
Future expansion possible
The new facility is equipped with the latest technology and meets international specifications. It is designed to meet local regulatory requirements and also World Health Organisation standards. The design of the new facility is determined by the current tablet and capsule production requirements, and the plant is capable of producing approximately 1.75-billion units and packaging of two-billion units, annually. Possible expansion could bring about the addition of new products. "The capacity to manufacture locally will meet the South African government's intention to strengthen the local pharmaceutical manufacturing industry and is expected to further the company's aim of becoming a more significant provider of pharmaceuticals to the state," said Ranbaxy South Africa CEO Saxen van Coller.Affordable generic medicines
Ranbaxy South Africa, headquartered in Centurion, is engaged in the sale and distribution of generic prescription products in the South African healthcare system. The company also offers high-quality, affordable, generic anti-retroviral medicines to needy patients in Africa, supporting African governments in their efforts to control the HIV/Aids epidemic. Ranbaxy Laboratories is India's largest pharmaceutical company, and is majority-owned by Japanese global pharmaceutical major Daiichi Sankyo Group. SAinfo reporter
Would you like to use this article in your publication or on your website? See: Using SAinfo material
(Photo: The Science Museum)
Related links
Related articles
- Merck expands South Africa presence
- Adcock Ingram expands in West Africa
- News Cafe opens in India
- GSK buys into Aspen Pharmacare
- Datatec expands via India
- SA's pharmaceutical success story
- SA pharma expands global presence
- SA pharma enters Latin America
- Indian pharma enters SA market
- Tata chooses South Africa
- SA in massive Indian airport deal
